Vorozole
 | |
| Clinical data | |
|---|---|
| Synonyms | R-76713 |
| ATC code | |
| Pharmacokinetic data | |
| Bioavailability | Very high |
| Metabolism | Hepatic |
| Elimination half-life | 8 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C16H13ClN6 |
| Molar mass | 324.768 g/mol |
| 3D model (JSmol) | |
| |
  | |
Vorozole (developmental code name R-76713) is an imidazole based competitive inhibitor of the aromatase enzyme. It underwent clinical testing for evaluation for use as an antineoplastic agent; however it was withdrawn from testing when no difference was detected in the duration of median survival as compared to the progestational agent megestrol acetate and research instead focused on the other third generation aromatase inhibitors anastrozole, letrozole and exemestane.[1]
References
- ↑ Goss PE (1998). "Pre-clinical and clinical review of vorozole, a new third generation aromatase inhibitor" (PDF). Breast Cancer Res. Treat. 49. Suppl 1: S59–65, discussion S73–7. doi:10.1023/a:1006052923468. PMID 9797019.
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.